Trial Profile
Phase II placebo controlled trial of IMO-2125 in patients with T3/T4 primary melanoma scheduled to undergo a combined re-excision and sentinel node biopsy procedure
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Tilsotolimod (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 02 Aug 2018 According to the Idera Pharmaceuticals media release,The principal investigators initiating this are Bas Koster, MD and Tanja de Gruijl, PhD at The VU University Medical Center, Amsterdam, the Netherlands.
- 23 Apr 2018 New trial record